CXCR4 and B-cell neoplasm: CD19-targeted immunotherapies such as mAbs and CAR-T cells have already demonstrated clinical success across multiple B-cell neoplasms; however, resistance mechanisms driven by CXCR4-mediated microenvironmental protection may similarly undermine these therapeutic approaches.